CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that
it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties,
at the International Conference on Opioids, which will be held in Boston on June 5-7, 2016.
Details of the poster presentations are as follows:
Date: Monday, June 6, 2016
Times: 10:00-10:30 am, 12:30-1:30 pm, and 3:30-4:00 pm ET
Location: The Joseph B. Martin Conference Center at Harvard Medical School
Poster #49: “Safety, Tolerability, and Efficacy of Xtampza™ ER (Oxycodone DETERx®
extended-release) Treatment in Subjects 65 Years and Older”
Poster #50: “Sprinkle Administration of Xtampza™ ER (Oxycodone DETERx® extended-release): An
Abuse-deterrent, Extended-release Formulation”
For more information on the International Conference on Opioids, visit http://www.opioidconference.org/ .
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is
designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza™ ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/
Contact: Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com
